CABOZANTINIB S-MALATE Drug Patent Profile

« Back to Dashboard

Which patents cover Cabozantinib S-malate, and when can generic versions of Cabozantinib S-malate launch?

Cabozantinib S-malate is a drug marketed by MSN and is included in one NDA.

The generic ingredient in CABOZANTINIB S-MALATE is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cabozantinib S-malate

A generic version of CABOZANTINIB S-MALATE was approved as cabozantinib s-malate by MSN on August 14^th, 2026.

Summary for CABOZANTINIB S-MALATE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	42
Patent Applications:	1,791
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CABOZANTINIB S-MALATE
DailyMed Link:	CABOZANTINIB S-MALATE at DailyMed

Recent Clinical Trials for CABOZANTINIB S-MALATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 2
National Cancer Institute (NCI)	Phase 2/Phase 3
Children's Oncology Group	Phase 2/Phase 3

See all CABOZANTINIB S-MALATE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for CABOZANTINIB S-MALATE

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for CABOZANTINIB S-MALATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CABOMETYX	Tablets	cabozantinib s-malate	20 mg, 40 mg and 60 mg	208692	1	2019-08-16

US Patents and Regulatory Information for CABOZANTINIB S-MALATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msn	CABOZANTINIB S-MALATE	cabozantinib s-malate	TABLET;ORAL	213878-001	Aug 14, 2026	AB	RX	No	No
Msn	CABOZANTINIB S-MALATE	cabozantinib s-malate	TABLET;ORAL	213878-002	Aug 14, 2026	AB	RX	No	No
Msn	CABOZANTINIB S-MALATE	cabozantinib s-malate	TABLET;ORAL	213878-003	Aug 14, 2026	AB	RX	No	No

Cabozantinib S-Malate Market Dynamics, Financial Trajectory, Patents, and Generic Risk

Last updated: October 20, 2026

Cabozantinib S-malate is a commercially established multikinase inhibitor marketed as Cabometyx and Cometriq. Cabometyx drives most of the franchise value through renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer indications. Exelixis retains the principal economic interest in the U.S., while Ipsen commercializes the product in many international markets.

The asset’s market outlook remains favorable through the late 2020s because of broad oncology labeling, combination use with nivolumab, physician familiarity, and a delayed generic-entry profile. The principal risks are dependence on renal cell carcinoma revenue, competition from lenvatinib and immune-oncology combinations, treatment sequencing changes, and eventual ANDA entry after negotiated patent settlements.

What is cabozantinib S-malate and how is it marketed?

Cabozantinib is a small-molecule tyrosine kinase inhibitor supplied as the S-malate salt. It inhibits multiple targets, including MET, VEGFR2, AXL, RET, KIT, and FLT3. The product is marketed under two principal brands:

Brand	Formulation	Primary company	Main indications
Cabometyx	Tablets	Exelixis in the U.S.; Ipsen internationally	Renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer
Cometriq	Capsules	Exelixis in the U.S.; international partners	Progressive or metastatic medullary thyroid cancer

The two products contain cabozantinib but are not interchangeable. Their dosage forms, strengths, indications, and regulatory product identifiers differ.

The FDA approved Cometriq in 2012 for metastatic medullary thyroid cancer. Cabometyx received FDA approval in 2016 for advanced renal cell carcinoma after prior antiangiogenic therapy. The FDA later expanded Cabometyx into hepatocellular carcinoma after prior sorafenib, differentiated thyroid cancer, and first-line renal cell carcinoma in combination with nivolumab. [1]

What are the FDA approvals and exclusivity milestones for cabozantinib?

Cabometyx has the more important commercial label because renal cell carcinoma represents the largest addressable market.

Date	Regulatory event	Commercial significance
November 2012	FDA approval of Cometriq	Established cabozantinib in medullary thyroid cancer
April 2016	FDA approval of Cabometyx for advanced RCC after prior antiangiogenic therapy	Created the primary commercial franchise
January 2019	FDA approval for HCC after prior sorafenib	Expanded use into liver cancer
January 2021	FDA approval with nivolumab for previously untreated advanced RCC	Moved cabozantinib into first-line combination therapy
June 2021	FDA approval for differentiated thyroid cancer refractory to radioactive iodine	Added a later-line thyroid cancer market

The Cabometyx label is commercially stronger than Cometriq because RCC treatment duration is generally longer and the eligible patient population is materially larger. Cabometyx also benefits from combination use with nivolumab, although the combination exposes Exelixis to competition from other immune-oncology and VEGF-directed regimens.

Cabozantinib is a small molecule, so biosimilar approval under the FDA’s 351(k) pathway does not apply. Future competition will come primarily through abbreviated new drug applications, or ANDAs, rather than biosimilar applications.

What patents protect Cabometyx and Cometriq?

Cabozantinib is protected by several patent categories:

1. Core chemical-compound patents.
2. Salt and pharmaceutical-composition patents.
3. Method-of-treatment patents.
4. Formulation and dosage-regimen patents.
5. Combination-treatment patents, including use with nivolumab.
6. Pediatric-exclusivity and regulatory exclusivity rights where applicable.

The most commercially important protection is the Orange Book-listed patent estate for Cabometyx tablets. The relevant patents cover the active ingredient, pharmaceutical compositions, and methods of treating cancer with cabozantinib. Patent terms extend into the late 2020s and early 2030s, depending on the patent family and applicable patent-term adjustments.

The exact patent position varies by strength, product, indication, and Orange Book update. The FDA Orange Book should be treated as the controlling source for currently listed U.S. patents and pediatric exclusivity. [2]

How strong is the cabozantinib patent estate?

The estate is commercially meaningful but not impenetrable.

Protection layer	Strength	Generic vulnerability
Core active-ingredient patents	High historically	Expiration and validity challenges determine value
Tablet composition and salt claims	Moderate to high	ANDA applicants may challenge non-core claims
Method-of-use claims	Moderate	Vulnerable to skinny-label and non-infringement strategies
Nivolumab combination claims	Moderate	Less effective against standalone cabozantinib tablets
Manufacturing and process know-how	Moderate	Can raise entry costs but does not always block ANDA approval
Regulatory exclusivity	Limited relative to patent term	Does not replace patent protection

Cabozantinib’s protection is therefore based on a layered estate rather than a single blocking patent. Method-of-use patents can narrow generic labeling protection because an ANDA applicant may omit protected indications under a section viii statement, subject to the scope of the patent claims and FDA labeling requirements.

When does cabozantinib lose exclusivity?

The practical U.S. loss-of-exclusivity date appears to be later than the earliest expiration of individual patents. Exelixis has reported patent litigation and settlement agreements with ANDA applicants that provide for delayed generic entry, generally targeting entry around 2031 for Cabometyx products, subject to settlement terms, patent outcomes, and regulatory events. [3]

A simplified exclusivity timeline is:

Period	Expected market position
2025-2027	Branded market with substantial patent protection
2028-2030	Increasing Paragraph IV litigation and settlement pressure
Around 2031	Potential first generic Cabometyx entry under reported settlement frameworks
After first entry	Rapid price erosion and share loss likely in routine oral therapy

Cometriq and Cabometyx should not be assigned the same effective loss-of-exclusivity date without reviewing their separate Orange Book listings and litigation records. Cabometyx is the financially dominant asset and the main target for ANDA challenges.

Which companies are challenging cabozantinib patents?

Generic companies have filed or pursued ANDA challenges against Cabometyx patents. Publicly reported litigation and settlement activity has involved multiple generic applicants, including Teva and other manufacturers. The disputes have generally centered on patent validity, enforceability, and infringement under the Hatch-Waxman framework.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. The filing of a Paragraph IV notice can trigger a 30-month stay of FDA approval if the branded sponsor brings litigation within the statutory period. A settlement can end the litigation while permitting a defined future launch date.

The commercial effect of these settlements is important. They can convert uncertain litigation timing into a relatively predictable entry date, but they may also permit earlier entry if a different generic applicant wins a judgment, reaches a separate agreement, or relies on a patent not covered by the settlement.

What is the Orange Book status of cabozantinib?

Cabometyx is listed in the FDA Orange Book as a prescription drug product with associated patents and exclusivity information. The Orange Book records are relevant to ANDA certification, patent litigation, and approval timing. Cometriq has separate listings because it is a different dosage form and product presentation.

The Orange Book does not provide a complete measure of commercial protection. It may not capture:

• Unlisted manufacturing know-how.
• Trade secrets involving synthesis or impurity control.
• Foreign patents.
• Contractual launch restrictions.
• Patent claims that are not listed for a particular product.
• Litigation outcomes or settlement provisions not yet reflected in the database.

For investment analysis, the Orange Book should be combined with USPTO records, federal court dockets, FDA approval history, and company settlement disclosures.

What are the principal market drivers for cabozantinib?

Renal cell carcinoma is the core growth and revenue driver

Cabozantinib has a strong position in advanced RCC because it is used after prior therapy and in combination with nivolumab in the first-line setting. The product competes in a treatment environment where VEGF inhibition, immune checkpoint inhibition, and sequential therapy are all established.

Its commercial advantages include:

• Multiple RCC lines of therapy.
• Use in combination with nivolumab.
• Activity in patients previously treated with immune checkpoint inhibitors.
• Established use by academic and community oncologists.
• Oral administration.

The key limitation is that first-line RCC increasingly involves combination regimens, including pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, and nivolumab plus ipilimumab. Cabozantinib must defend both its first-line combination position and its later-line monotherapy use.

HCC provides diversification but not equal revenue scale

Cabometyx is approved for hepatocellular carcinoma after prior sorafenib. The market is competitive, and treatment sequencing varies according to liver function, prior immunotherapy, tolerability, and regional practice.

Cabozantinib benefits from activity after prior systemic therapy, but the HCC opportunity is constrained by:

• Earlier use of atezolizumab-bevacizumab and durvalumab-based regimens.
• Patient attrition after first-line therapy.
• Liver-function limitations.
• Competition from regorafenib and other targeted agents.

Thyroid cancer is strategically useful but smaller

Cabozantinib has differentiated and medullary thyroid cancer indications. These provide regulatory diversification and reinforce the scientific value of the compound, but they contribute less revenue than RCC.

Cometriq is a smaller product relative to Cabometyx. It has specialized demand in medullary thyroid cancer and is less exposed to broad generic substitution because of the smaller patient base, but its strategic importance is lower.

How has cabozantinib revenue developed?

Exelixis has reported sustained growth in cabozantinib revenue as the product expanded from later-line RCC into first-line combination therapy and additional tumor types. Public company reporting indicates that cabozantinib represents the overwhelming majority of Exelixis’ product revenue and a substantial share of its total revenue. [3]

An indicative trajectory based on company-reported results is:

Fiscal year	Cabozantinib franchise trend	Main driver
2020	Established growth platform	RCC demand and expanded Cabometyx use
2021	Accelerating	Nivolumab combination approval
2022	Continued expansion	Wider first-line RCC adoption
2023	High-scale oncology franchise	Mature U.S. demand and international contribution
2024	Continued growth, with a higher base	Persistent RCC utilization and partner sales

Exelixis’ total annual revenue reached approximately $2 billion in the 2024 period, with cabozantinib accounting for most of the product economics. Exact segmentation differs between U.S. net product revenue, collaboration revenue, royalties, and international partner revenue. Exelixis records its Ipsen relationship through collaboration and royalty arrangements rather than treating all international sales as direct U.S. product revenue. [3]

What is the financial exposure to cabozantinib?

Cabozantinib concentration creates both operating leverage and risk.

Financial factor	Effect
High U.S. brand penetration	Supports margin and cash generation
Limited dependence on manufacturing capacity	Reduces physical supply-chain risk
Strong RCC demand	Supports recurring prescription volume
Single-franchise concentration	Increases exposure to one asset’s patent and clinical risks
Generic entry after 2030	Creates a material revenue step-down risk
International licensing	Provides geographic reach but reduces direct economics

The principal valuation question is whether Exelixis can replace cabozantinib revenue before generic entry. The company has pursued pipeline assets and business-development transactions to reduce dependence on the franchise, but cabozantinib remains the central cash-generating asset.

How does cabozantinib compare with competing oncology drugs?

Drug	Company	Main competitive area	Relative position
Cabozantinib	Exelixis/Ipsen	RCC, HCC, thyroid cancer	Broad label and strong later-line RCC position
Lenvatinib	Eisai	RCC combination therapy, HCC, thyroid cancer	Strong pembrolizumab and RCC combination competitor
Axitinib	Pfizer	RCC, especially with pembrolizumab	Established VEGFR inhibitor with earlier generic pressure
Regorafenib	Bayer	HCC and gastrointestinal tumors	Relevant post-sorafenib competitor
Sunitinib	Pfizer	RCC	Older VEGFR standard with generic competition
Pembrolizumab combinations	Merck	RCC and multiple cancers	Expands immunotherapy-driven first-line competition
Nivolumab combinations	Bristol Myers Squibb	RCC	Direct partner in Cabometyx first-line regimen

Cabozantinib’s differentiation is its activity across MET, AXL, and VEGFR pathways, its use after immune checkpoint therapy, and its combination with nivolumab. Its commercial vulnerability is that many oncologists select regimens based on the full combination, biomarker profile, toxicity, payer policy, and sequencing rather than on cabozantinib alone.

What manufacturing and intellectual-property barriers affect generic entry?

Cabozantinib is an oral small molecule, so manufacturing barriers are lower than those for a biologic. Generic manufacturers still must demonstrate pharmaceutical equivalence and bioequivalence, meet impurity and stability specifications, and reproduce the relevant salt and dosage form.

Potential barriers include:

• Controlled synthesis of the S-malate salt.
• Impurity and degradation-product control.
• Tablet dissolution and bioequivalence requirements.
• Patent claims covering formulation or treatment methods.
• Commercial scale-up and oncology distribution.
• Regulatory review of manufacturing sites.

These barriers support quality and timing control but are unlikely to prevent competition indefinitely after patent expiry. The most significant barrier remains the patent and litigation timetable.

What generic launch scenarios exist for Cabometyx?

Scenario 1: Settled entry around 2031

This is the base-case commercial scenario if reported settlements remain effective and no earlier invalidity ruling changes the timetable. Revenue would likely decline rapidly after the first ANDA launch, with net price reductions and payer-driven substitution.

Scenario 2: Earlier launch after patent loss

An adverse validity or infringement decision could permit earlier generic entry. This would cause a sharper valuation impact because Cabometyx has high revenue concentration within Exelixis.

Scenario 3: Delayed or fragmented entry

Multiple patents, manufacturing issues, or regulatory delays could produce a later first launch or staggered generic participation. This would preserve branded economics for longer but is less favorable to generic companies.

Scenario 4: Authorized generic or branded-generic strategy

Exelixis or a partner could use an authorized generic to retain part of the post-LOE market. This could reduce third-party generic margins but would also accelerate branded price erosion.

What licensing deals affect cabozantinib?

Exelixis granted Ipsen rights to commercialize cabozantinib outside the United States and Japan in a 2016 collaboration. The arrangement expanded international reach while giving Exelixis access to upfront payments, milestones, and royalties or profit participation. [4]

Japan has involved a separate commercial and licensing structure associated with Takeda. International agreements reduce Exelixis’ direct sales contribution but diversify commercialization costs and support regulatory access.

The Ipsen relationship is strategically important because international cabozantinib sales extend the product’s commercial life beyond the U.S. patent cycle. Geographic economics vary according to local patent terms, pricing controls, reimbursement, and generic substitution rules.

What is the competitive and geographic outlook?

United States

The U.S. is the primary value driver because of higher net pricing, first-line RCC use, and Exelixis’ direct commercial control. The main risk is a concentrated patent cliff in the early 2030s.

Europe

Ipsen’s commercial infrastructure supports broad availability, but price controls and health-technology assessment requirements reduce net revenue per patient. Country-level generic entry may occur at different times depending on national patent and regulatory rules.

Japan

Japan is a smaller but strategically relevant market. Local reimbursement, regulatory requirements, and partner arrangements influence revenue timing and profitability.

Emerging markets

Access is more sensitive to price, reimbursement, local competition, and supply arrangements. These markets can extend unit volume but generally contribute less profit per prescription.

What patent litigation affects cabozantinib?

The material litigation is Hatch-Waxman litigation involving Cabometyx ANDA applicants and Exelixis patent rights. The key issues are expected to include:

• Whether asserted patent claims are valid.
• Whether generic tablets infringe composition or method claims.
• Whether ANDA labeling omits patented indications.
• Whether patent settlements permit entry before full expiration.
• Whether later-listed patents create additional litigation.

A settlement is commercially preferable to prolonged uncertainty for both parties when the branded product has a large revenue base and generic applicants can secure a defined future launch date. Settlement terms do not eliminate generic risk; they quantify and postpone it.

Key Takeaways

• Cabozantinib S-malate is marketed mainly as Cabometyx and, to a lesser extent, Cometriq.
• Cabometyx is the principal value driver because of its RCC franchise and nivolumab combination.
• Exelixis remains highly dependent on cabozantinib cash flow.
• The product is a small molecule, so future competition will come through ANDAs rather than biosimilars.
• Orange Book patents, method-of-use claims, and settlements create meaningful protection into the early 2030s.
• Reported generic settlements point to potential Cabometyx entry around 2031, although litigation and regulatory events can alter timing.
• Lenvatinib, axitinib, pembrolizumab combinations, and other RCC regimens are the main competitive threats.
• The major financial risk is a concentrated post-2030 revenue decline before replacement products reach commercial scale.
• Ipsen and other regional partners extend geographic reach but reduce Exelixis’ direct international economics.
• Cabozantinib remains a high-value oncology franchise with strong near-term cash generation and a defined long-term patent-cliff risk.

FAQs

Is cabozantinib S-malate the same as Cabometyx?

Cabozantinib S-malate is the active pharmaceutical ingredient salt used in Cabometyx and Cometriq. The products are not interchangeable because they use different dosage forms, strengths, and approved indications.

Does cabozantinib have biosimilar competition?

No. Cabozantinib is a small molecule. Competition will occur through generic ANDA products, not FDA biosimilars.

Which cabozantinib product has the greater commercial value?

Cabometyx has substantially greater commercial value than Cometriq because it covers larger RCC, HCC, and differentiated thyroid cancer markets and includes a first-line RCC combination indication.

What drug is the closest competitor to cabozantinib in renal cell carcinoma?

Lenvatinib is one of the closest targeted competitors, particularly in combination regimens. Axitinib, pembrolizumab combinations, nivolumab combinations, and other VEGF-directed therapies also compete directly or indirectly.

What happens to Exelixis revenue when Cabometyx loses exclusivity?

Revenue would likely decline materially after generic entry because oral oncology products are vulnerable to payer substitution and price competition. The magnitude depends on the number of generic entrants, settlement timing, authorized-generic strategy, and the success of Exelixis’ replacement pipeline.

References

1. U.S. Food and Drug Administration. (2024). Cabometyx (cabozantinib) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. Exelixis, Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission. https://www.sec.gov
4. Ipsen. (2016). Ipsen and Exelixis enter into a licensing agreement for cabozantinib outside the United States. https://www.ipsen.com